Intangible Assets

No filing evidence provided for patents, proprietary formulations, or regulatory exclusivity, so there is no visible legal barrier that would let ZSQR sustain pricing power versus peers.

The supplied FMP data show deeply negative ROIC and ROCE, which is inconsistent with a durable intangible-led advantage that would normally support superior margins versus peers.

With no disclosed brand premium, clinical data moat, or protected IP cited in the provided materials, any intangible advantage appears replicable rather than structurally differentiated versus peers.

Switching Costs

No evidence is provided that customers face workflow lock-in, integration costs, or contractual penalties that would make switching away from ZSQR materially costly versus peers.

The negative ROIC and very low asset turnover suggest the business is not yet monetizing a sticky installed base in a way that would indicate strong retention economics versus peers.

Absent filing-based proof of recurring usage dependence or embedded mission-critical functionality, switching costs appear limited and unlikely to protect margins over 5–10 years versus peers.

Network Effects

The provided materials do not show a user, data, or ecosystem flywheel that would make ZSQR more valuable as adoption rises versus peers.

No evidence is given of multi-sided participation, platform dependency, or data accumulation that compounds competitive advantage over time.

Without observable network-driven retention or peer dependence, network effects appear negligible and do not support durable pricing power.

Cost Advantage

The TTM ROIC and ROCE are both negative, which indicates ZSQR is not currently converting operations into a cost position superior to peers.

Asset turnover of 0.0208 is extremely low, suggesting the company is not operating with a scale-efficient cost structure that would pressure peer pricing.

No filing evidence is provided for lower input costs, manufacturing leverage, or process advantages that would create a durable cost edge versus peers.

Efficient Scale

No evidence is provided that ZSQR serves a niche where market size is too small to support multiple efficient competitors, which is the core condition for efficient-scale protection versus peers.

The negative profitability metrics imply the company is not yet extracting the economics typically associated with a protected niche or natural bottleneck.

Without proof of regulated scarcity, exclusive access, or a capacity-constrained market structure, efficient scale does not appear to be a meaningful moat driver.

Overall Score

Based on the provided FMP metrics and the absence of filing-based evidence for protected IP, switching costs, network effects, cost advantage, or efficient scale, ZSQR appears to have a weak and largely replicable moat versus peers.